Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number

Journal of Clinical Oncology

Volumn 26, Issue 19, 2008, Pages 3138-3146

  Worden, Francis P ^a   Kumar, Bhavna ^a   Lee, Julia S ^a   Wolf, Gregory T ^a   Cordell, Kitrina G ^a   Taylor, Jeremy M G ^a   Urba, Susan G ^a   Eisbruch, Avraham ^a   Teknos, Theodoros N ^a   Chepeha, Douglas B ^a   Prince, Mark E ^a   Tsien, Christina I ^a   D'Silva, Nisha J ^a   Yang, Kun ^a   Kurnit, David M ^a   Mason, Heidi L ^a   Miller, Tamara H ^a   Wallace, Nancy E ^a   Bradford, Carol R ^a   Carey, Thomas E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; INFUSION FLUID; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALTERNATIVE MEDICINE; ANEMIA; ARTICLE; BIOPSY TECHNIQUE; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MANDIBULAR OSTEORADIONECROSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; ORGAN PRESERVATION; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; SENSORY NEUROPATHY; SEX; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AREA UNDER THE CURVE; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; OROPHARYNX TUMOR; PAPILLOMA VIRUS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PACLITAXEL; PAPILLOMAVIRIDAE; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 49249135921     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.7597     Document Type: Article

References (48)

1. Shiboski CH, Schmidt BL, Jordan RC: Tongue and tonsil carcinoma: Increasing trends in the US population ages 20-44 years. Cancer 103:1843-1849, 2005
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
3. Bagnardi V, Blangiardo M, La Vecchia C, et al: Alcohol consumption and the risk of cancer: A meta-analysis. Alcohol Res Health 25:263-270, 2001
4. Lewin F, Norell SE, Johansson H, et al: Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: A population-based case-referent study in Sweden. Cancer 82:1367-1375, 1998
5. D'Souza G, Kreimer AR, Viscidi R, et al: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944-1956, 2007
6. Fakhry C, Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24:2606-2611, 2006
7. Li G, Sturgis EM: The role of human papillomavirus in squamous carcinoma of the head and neck. Curr Oncol Rep 8:130-139, 2006
8. Ringstrom E, Peters E, Hasegawa M, et al: Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8:3187-3192, 2002
9. van Houten VM, Snijders PJ, van den Brekel MW, et al: Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 93:232-235, 2001
10. Lindel K, Beer KT, Laissue J, et al: Human papillomavirus positive squamous cell carcinoma of the oropharynx: A radiosensitive subgroup of head and neck carcinoma. Cancer 92:805-813, 2001
11. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000
12. Li W, Thompson CH, O'Brien CJ, et al: Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 106:553-558, 2003
13. Mellin H, Dahlgren L, Munck-Wikland E, et al: Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 102:152-158, 2002
14. Badaracco G, Venuti A, Morello R, et al: Human papillomavirus in head and neck carcinomas: Prevalence, physical status and relationship with clinical/pathological parameters. Anticancer Res 20:1301-1305, 2000
15. Pintos J, Franco EL, Black MJ, et al: Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer 85:1903-1909, 1999
16. Domenge C, Hill C, Lefebvre JL, et al: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83:1594-1598, 2000
17. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265-272, 1994
18. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
19. Urba S, Wolf G, Eisbruch A, et al: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 24:593-598, 2006
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. National Cancer Institute: Investigator's Handbook: A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by Division of Cancer Treatment and Diagnosis, National Cancer Institute. Bethesda, MD, National Cancer Institute, 1993
22. Eisbruch A, Marsh LH, Martel MK, et al: Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: Assessment of target coverage and noninvolved tissue sparing. Int J Radiat Oncol Biol Phys 41:559-568, 1998
23. Vineberg KA, Eisbruch A, Coselmon MM, et al: Is uniform target dose possible in IMRT plans in the head and neck? Int J Radiat Oncol Biol Phys 52:1159-1172, 2002
24. Kumar B, Cordell KG, Lee JS, et al: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 10.1200/JCO.2007.12.7662, 2007
25. Yang H, Yang K, Khafagi A, et al: Sensitive detection of human papillomavirus in cervical, head/ neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A 102:7683-7688, 2005
26. Obiso R, Lorincz A: Digene Corporation. Pharmacogenomics 5:129-132, 2004
27. Carey VJ: Using hypertext and the internet for structure and management of observational studies. Stat Med 16:1667-1682, 1997
28. Adelstein DJ, Saxton JP, Lavertu P, et al: Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 20:1405-1410, 2002
29. Garden AS, Harris J, Vokes EE, et al: Preliminary results of Radiation Therapy Oncology Group 9703: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22:2856-2864, 2004
30. Urba SG, Moon J, Giri PG, et al: Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: A Southwest Oncology Group trial. J Clin Oncol 23:88-95, 2005
31. Urba S, Worden F, Carey T, et al: One cycle of induction chemotherapy (IC) to select for organ preservation for patients (PTS) with advanced squamous carcinoma of the oral cavity (SCCOC). J Clin Oncol 23:16S, 2005 (suppl; abstr 5555)
32. Li W, Thompson CH, Cossart YE, et al: The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck 26:1-9, 2004
33. Licitra L, Perrone F, Bossi P, et al: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630-5636, 2006
34. Reimers N, Kasper HU, Weissenborn SJ, et al: Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120:1731-1738, 2007
35. Sisk EA, Soltys SG, Zhu S, et al: Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 24:841-849, 2002
36. Albers A, Abe K, Hunt J, et al: Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65:11146-11155, 2005
37. Forastiere AA, Metch B, Schuller DE, et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992
38. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004
39. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
40. Brucher BL, Weber W, Bauer M, et al: Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg 233:300-309, 2001
41. Flamen P: Positron emission tomography in colorectal cancer. Best Pract Res Clin Gastroenterol 16:237-251, 2002
42. Mac Manus MP, Hicks RJ, Matthews JP, et al: Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21:1285-1292, 2003
43. Swisher SG, Maish M, Erasmus JJ, et al: Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78:1152-1160, 2004
44. Bourhis J, Le Maitre A, Baujat B, et al: Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 19:188-194, 2007
45. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data-MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
46. Calais G, Pointreau Y, Alfonsi CS, et al: Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer: Preliminary results of GORTEC 2000-01. J Clin Oncol 24:18s, 2006 (suppl; abstr 5506)
47. Hitt R, Grau J, Lopez-Pousa A, et al: Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. CRT alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 24:18s, 2006 (suppl; abstr 5515)
48. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636-8645, 2005